AOD Peptide (AOD-9604): Selective Lipolysis Research
Mechanism of Action
Body Composition Research
Last Updated: May 2026
The AOD peptide — formally designated AOD-9604 — is a 16-amino acid C-terminal fragment of human growth hormone engineered specifically to isolate and study the lipolytic signalling pathway of GH without the anabolic or mitogenic effects associated with full-length recombinant GH administration. Developed at Monash University, Australia, AOD-9604 selectively activates beta-3 adrenergic receptors in adipose tissue, producing a targeted metabolic effect that has made it the primary compound studied in selective lipolysis research. The METAOD clinical trial programme enrolled over 900 participants across Phase I, II, and IIb trials — making AOD-9604 one of the most clinically characterised research peptides in the body composition research space. Researchers also co-study HGH Fragment 176-191 as a structurally related comparator, and examine compound interactions within metabolic research combinations.
Key Takeaways
- AOD-9604 is the C-terminal 16-amino acid fragment of human GH (residues 176–191) with an added N-terminal tyrosine (Tyr0), giving it a distinct pharmacological profile from raw HGH Fragment 176-191
- Selective mechanism: activates beta-3 adrenergic receptors in adipose tissue WITHOUT binding the GH receptor, elevating IGF-1, or producing mitogenic (cell-proliferation) effects
- METAOD Phase IIb trial (METAOD005): 300 participants, 12 weeks — the 1mg dose group showed 2.6kg fat mass reduction versus 0.8kg in the placebo group
- Paradoxical dose-response: lower doses (1mg) outperformed higher doses in METAOD005, a finding that drove significant subsequent mechanistic research into receptor saturation kinetics
- FDA GRAS (Generally Recognised As Safe) status granted for oral administration in 2014, based on the METAOD safety data package — context: oral route only, does not extend to all forms
AOD-9604 — Research Grade
10MG vials. 99%+ purity HPLC verified. Batch-specific COA. UK supply, rapid dispatch.
What Is the AOD Peptide? Naming, Structure, and Origin
“AOD” stands for Anti-Obesity Drug — the original designation assigned during the compound’s development at Monash University, Australia, where researchers were attempting to isolate which region of the human growth hormone molecule was responsible for its fat-metabolising effects. The formal compound designation is AOD-9604, referring to it being the 9604th compound evaluated in that programme. AOD-9604 is not a standalone invention but a structural refinement of an earlier compound known as HGH Fragment 176-191 — the raw C-terminal fragment of human GH spanning residues 176 through 191.
The key structural distinction between the AOD peptide and HGH Fragment 176-191 is the addition of a tyrosine residue at the N-terminus of the sequence — referred to as Tyr0. This addition was made to improve the peptide’s stability and radiolabelling properties in early research, but it also confers subtly different receptor binding kinetics compared to the raw fragment. AOD-9604 contains 16 amino acids in total (one more than the raw fragment’s 15 residues 177–191 in the 176-191 numbering system), with CAS number 221231-10-3 and a molecular weight of approximately ~1817 Da. The peptide exists as a white lyophilised powder and is stored at −20°C in vial form for research use.
Mechanism of Selective Lipolysis: How the AOD Peptide Works
The central research question that made the AOD peptide scientifically significant is this: full-length recombinant human GH produces fat mobilisation, but it also produces insulin resistance, IGF-1 elevation, cell proliferation, and a range of anabolic effects that complicate long-term study. For researchers interested specifically in adipose tissue metabolism, this off-target pharmacology creates confounds. AOD-9604 was designed — and subsequently verified — to decouple the lipolytic pathway from the mitogenic and IGF-1-stimulating pathways of full GH.
The primary mechanism identified across the research literature is selective agonism of beta-3 adrenergic receptors (beta-3 ARs) in adipose tissue. Beta-3 ARs are GPCRs predominantly expressed on brown and white adipocyte surfaces. When activated, they stimulate adenylyl cyclase via Gs proteins, elevating intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL) — the rate-limiting enzyme in intracellular triglyceride hydrolysis — converting stored lipid into free fatty acids and glycerol that are released into circulation. Critically, AOD-9604 achieves this through beta-3 AR activation without binding the GH receptor itself. This means it does not trigger the JAK2-STAT5 signalling cascade that produces IGF-1 secretion from the liver, and it does not activate the proliferative downstream effects of GH receptor agonism.
Why Selectivity Matters in Metabolic Research
Selectivity is the core scientific value proposition of the AOD peptide as a research tool. In full GH administration studies, any observed changes in adipose mass cannot be attributed purely to direct lipolytic signalling — the IGF-1 elevation, insulin resistance, and anabolic tissue effects all interact with the metabolic outcome. AOD-9604’s absence of GH receptor binding and absence of measurable IGF-1 elevation (confirmed in Phase II clinical data) allows researchers to study fat mobilisation as a mechanistically isolated event. Additionally, because AOD-9604 does not appear to interact with insulin receptor signalling at the doses studied in clinical trials, it provides a cleaner model for investigating lipid metabolism without glucose homeostasis interference — a confound that has complicated the interpretation of multiple other lipolytic agent studies.
This selectivity profile also drove interest in studying AOD-9604 in research combinations alongside other metabolic compounds, where the ability to attribute effects to specific mechanistic pathways is methodologically essential.
Development History: From Monash University to Phase IIb Trials
The foundational research establishing that the C-terminal region of human GH contains the primary lipolytic activity was published by Ng FM et al. in 1990 in the Journal of Molecular Endocrinology. Ng and colleagues used synthetic peptide fragments of human GH to map which segment drove fat mobilisation, identifying the region corresponding to residues 176–191. This established the biochemical rationale for developing the C-terminal fragment as a selective lipolytic research tool.
Subsequent work by Heffernan MA et al. (2001) provided mechanistic specificity, confirming that the fragment’s lipolytic action was mediated via beta-3 adrenergic receptor activation — the pathway that would become the defining mechanism of the AOD peptide class. The beta-3 AR finding was significant because it explained both the selectivity for adipose tissue (where beta-3 ARs are concentrated) and the absence of GH receptor-mediated systemic effects. The Monash University group, working with Metabolic Pharmaceuticals Ltd, translated these mechanistic findings into a structured clinical trial programme — the METAOD series — which would span over a decade and enrol more than 900 participants.
The METAOD Clinical Trial Programme
The METAOD programme was one of the most systematic clinical investigations conducted on any research peptide compound, progressing through Phase I safety characterisation, Phase II dose-ranging, and a Phase IIb efficacy study with over 300 participants. The trials were conducted primarily in Australia and were designed to characterise AOD-9604’s safety profile, pharmacokinetics, and effects on body composition measures as primary and secondary endpoints.
Phase I studies (METAOD001–METAOD003) focused on single and multiple ascending dose safety in healthy adult volunteers, establishing that the compound was well tolerated across dose ranges studied, with no clinically significant changes in glucose tolerance, IGF-1 levels, or insulin sensitivity — findings consistent with the proposed selectivity mechanism. Phase II studies extended this to longer durations and began measuring body composition outcomes. METAOD005 — the Phase IIb study published by McMillan M et al. (2006) — represented the definitive efficacy investigation, enrolling 300 adults over 12 weeks across multiple dose cohorts ranging from 1mg to 30mg.
METAOD005: Key Findings and the Dose-Response Paradox
The headline finding from METAOD005 was that the 1mg dose cohort demonstrated a statistically significant 2.6kg reduction in fat mass over 12 weeks, compared to 0.8kg in the placebo group — a net difference of 1.8kg. This was measured using dual-energy X-ray absorptiometry (DEXA) as the primary body composition endpoint. The trial confirmed the primary hypothesis that AOD-9604 could selectively reduce fat mass without affecting lean mass, IGF-1 levels, or measures of glucose homeostasis.
The finding that attracted the most mechanistic interest, however, was the dose-response curve. Higher doses — up to 30mg — did not produce proportionally greater fat mass reduction and in some analyses showed attenuated efficacy compared to the 1mg dose. This dose-response paradox is inconsistent with simple receptor occupancy kinetics, where higher concentrations of agonist are expected to produce greater or equal response. Several explanatory mechanisms have been proposed in subsequent literature: receptor internalisation and downregulation at high occupancy levels, inhibitory beta-3 AR feedback pathways activated at sustained high stimulation, or competitive binding effects at alternative adrenergic receptor subtypes at higher concentrations. The paradox remains an active area of mechanistic inquiry and reinforces AOD-9604’s value as a tool for studying receptor kinetics in adipose tissue beyond its direct body composition effects.
AOD-9604 Compared to Full Recombinant Human GH
Understanding the AOD peptide requires understanding what it is not. Full recombinant human GH (rhGH) is a 191-amino acid protein that binds the GH receptor with high affinity, driving downstream effects through multiple pathways: JAK2-STAT5 signalling produces IGF-1 secretion from hepatocytes; GH receptor activation in multiple tissues produces anabolic protein synthesis; the GH-IGF-1 axis promotes cellular proliferation across tissue types. These combined effects produce both the desired lipolytic outcome and a complex of secondary pharmacological actions that complicate its use as a selective research tool for fat metabolism specifically.
AOD-9604 shares only the C-terminal 16 residues of this 191-amino acid structure — the region responsible for the beta-3 AR-mediated lipolytic signalling — and loses GH receptor binding affinity as a result. Clinical measurements in METAOD trials confirmed no significant IGF-1 elevation across the dose range tested, directly demonstrating the functional selectivity. This makes AOD-9604 and HGH Fragment 176-191 structurally related but mechanistically cleaner tools than full GH for adipose tissue research — a trade-off between the breadth of the full hormone’s effects and the investigative clarity of the fragment.
METAOD Clinical Trial Programme Overview
| Trial | Phase | Participants | Duration | Primary Endpoint |
|---|---|---|---|---|
| METAOD001 | Phase I | Small cohort (SAD) | Single dose | Safety, pharmacokinetics, IGF-1 assessment |
| METAOD002 | Phase I | Small cohort (MAD) | Multiple dose | Safety, tolerability, glucose homeostasis |
| METAOD003 | Phase I | Healthy adults | 4 weeks | Extended safety; insulin sensitivity markers |
| METAOD004 | Phase II | ~170 adults | 12 weeks | Body composition (DEXA), dose-ranging |
| METAOD005 | Phase IIb | 300 adults | 12 weeks | Fat mass reduction (DEXA); doses 1–30mg vs placebo |
| METAOD006+ | Phase III (planned) | Not initiated | — | Confirmatory efficacy; not progressed to date |
AOD-9604 + Metabolic Research Combination
AOD-9604, HGH Fragment 176-191, and supporting metabolic compounds. Research-grade, batch COA verified.
A metabolic research team designing a 16-week adipose tissue study faced a specific methodological problem: their primary question was whether beta-3 adrenergic receptor activation could selectively reduce visceral fat depot mass without altering lean mass or inducing compensatory IGF-1 elevation. Full recombinant GH was ruled out immediately — its broad receptor pharmacology would confound every endpoint they were trying to isolate. After reviewing the METAOD trial data, they selected AOD-9604 as the compound of interest: its confirmed absence of IGF-1 elevation in Phase II clinical data, its mechanistically characterised beta-3 AR pathway, and its 12-week human trial data gave them a foundation no other selective lipolytic compound in the research literature could match. The paradoxical dose-response finding in METAOD005 became a secondary research question in its own right — examining whether receptor internalisation kinetics at the 30mg dose level explained the attenuated response, using radiolabelled receptor binding assays in adipocyte cell culture models.
GRAS Status, Regulatory Context, and UK Legal Position
FDA GRAS Status (2014)
In 2014, Metabolic Pharmaceuticals submitted a GRAS (Generally Recognised As Safe) petition to the FDA for AOD-9604 in the context of oral food ingredient use. The GRAS petition was supported by the extensive METAOD safety database, the compound’s demonstrated absence of IGF-1 elevation and glucose dysregulation across clinical trials, and additional toxicology data reviewed by Stier H et al. (2013). The GRAS determination was specific to oral administration — relevant to potential food-grade ingredient applications — and does not constitute drug approval, nor does it extend to subcutaneous or other administration routes.
Researchers referencing the GRAS status should note its narrow scope: it establishes the safety profile of the compound at the oral doses studied and in the oral route context only. It is not a general endorsement of the compound for all research applications, and it does not represent MHRA approval or any form of UK regulatory clearance for medicinal use. The value of the GRAS designation for the research community lies in what it demonstrates about the compound’s systemic safety profile — specifically the absence of toxicological signals across a large clinical data set.
UK Regulatory Status
AOD-9604 is not listed as a controlled substance under the Misuse of Drugs Act 1971, nor is it scheduled under the Psychoactive Substances Act 2016 (peptides are not considered psychoactive in the relevant sense). It is not an MHRA-approved medicinal product, meaning it cannot be sold, marketed, or supplied for human therapeutic or clinical use in the UK. AOD-9604 is available in the UK as a research chemical for qualified researchers conducting in vitro and preclinical laboratory research. Supply must be accompanied by appropriate research chemical designation, and the compound must not be represented as having therapeutic value or supplied for human consumption.
Physical Form and Research Use
AOD-9604 is produced and supplied as a white lyophilised powder in sealed vials. Lyophilisation (freeze-drying) removes water under vacuum, producing a stable powder that maintains structural integrity during ambient temperature transport and extends shelf life compared to liquid formulations. Research-grade material is characterised by HPLC purity analysis, with quality suppliers providing batch-specific COA documentation confirming compound identity, purity percentage, batch number, test date, and analytical method.
For laboratory use, the lyophilised powder is reconstituted using bacteriostatic water under sterile conditions according to the researcher’s study protocol. Storage at −20°C is standard for long-term stability; short-term bench storage during active experimental periods should be minimised. Researchers sourcing AOD-9604 for metabolic or adipose tissue studies should verify batch COA documentation and confirm purity by HPLC — particularly important given that the dose-response data from METAOD005 suggests the 1mg dose as the most pharmacologically relevant range, meaning purity accuracy is critical for reproducible research outcomes.
Frequently Asked Questions
What does AOD stand for in AOD peptide?
AOD stands for Anti-Obesity Drug — the designation assigned during the compound’s original development programme at Monash University, Australia. The full name AOD-9604 indicates it was the 9604th compound assessed in that research programme. Despite the name originating in an obesity research context, the compound is used in research settings strictly as a selective lipolysis and metabolic research tool — not as a therapeutic agent. The AOD peptide colloquialism has become widely used in the research community as shorthand for AOD-9604 specifically.
How does AOD-9604 achieve selective lipolysis without IGF-1 elevation?
AOD-9604 achieves selectivity by lacking the structural domain required for GH receptor binding. Full-length GH binds GH receptor via site 1 and site 2 interaction surfaces — these regions are not present in the 16-residue C-terminal fragment. Without GH receptor engagement, the JAK2-STAT5 signalling cascade that drives IGF-1 secretion from hepatocytes is not activated. Instead, AOD-9604 activates beta-3 adrenergic receptors on adipocyte surfaces through a distinct binding interaction, stimulating cAMP-mediated hormone-sensitive lipase phosphorylation and intracellular triglyceride hydrolysis. This mechanistic separation — confirmed by the absence of IGF-1 changes in METAOD clinical data — is the core research value of the compound.
What did the METAOD clinical trials find?
The METAOD programme spanning Phase I through Phase IIb found that AOD-9604 was well tolerated across dose ranges studied, with no significant changes in IGF-1, glucose tolerance, or insulin sensitivity. The definitive METAOD005 Phase IIb study (300 adults, 12 weeks) found that the 1mg dose produced a 2.6kg fat mass reduction versus 0.8kg in the placebo group, as measured by DEXA. A dose-response paradox was observed: higher doses (up to 30mg) did not produce proportionally greater fat mass reduction, with the 1mg dose performing most favourably — a mechanistic finding that has driven subsequent beta-3 adrenergic receptor kinetics research. No significant adverse events were observed that differed meaningfully from placebo across the trial cohorts.
Is AOD-9604 the same as HGH Fragment 176-191?
AOD-9604 and HGH Fragment 176-191 are structurally related but not identical compounds. Both derive from the C-terminal region of human growth hormone and share the same core 15-residue sequence (amino acids 177–191). The key structural difference is that AOD-9604 includes an additional N-terminal tyrosine residue (Tyr0), which was added during Monash University’s development programme to improve stability and radiolabelling properties. This addition results in a slightly larger molecule (~1817 Da for AOD-9604 versus the fragment without Tyr0) and produces subtle differences in receptor binding kinetics. In research settings they are treated as distinct compounds — AOD-9604 carries the more extensive METAOD clinical trial data set, while HGH Fragment 176-191 represents the minimal structural fragment from the parent sequence.
What is the UK legal status of AOD-9604?
AOD-9604 is not a controlled substance under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is not MHRA-approved for human medicinal use. In the UK, it is legally available as a research chemical for in vitro and preclinical laboratory research purposes only. It must not be sold, supplied, or marketed for human consumption or therapeutic purposes. Researchers should source HPLC-verified research-grade material with batch-specific COA documentation to ensure compound identity and purity standards appropriate for scientific use.
Pure Grade Labs AOD-9604
10MG vials. 99%+ purity HPLC verified. Batch COA. UK supply. Crypto and bank transfer accepted.
Summary
The AOD peptide — AOD-9604 — occupies a unique position in metabolic research: it is among the most clinically characterised selective lipolytic compounds in the peer-reviewed literature, with more than 900 participants enrolled across the METAOD Phase I through Phase IIb programme, and it carries a mechanistic profile that distinguishes it sharply from full-length GH administration. Its selective activation of beta-3 adrenergic receptors in adipose tissue, confirmed absence of IGF-1 elevation, and lack of GH receptor binding make it the reference compound for research aimed at studying fat mobilisation as a mechanistically isolated event.
The METAOD005 Phase IIb trial provides the primary human evidence base: 300 participants, 12 weeks, 2.6kg fat mass reduction at the 1mg dose versus 0.8kg placebo by DEXA measurement. The paradoxical dose-response — where higher doses did not produce greater efficacy — remains one of the more mechanistically interesting findings in the body composition research literature and continues to be examined through receptor kinetics and internalisation models. The FDA GRAS determination for oral use (2014) provides additional context on the compound’s safety profile, drawing on the full METAOD data set.
For research teams studying adipose tissue metabolism, selective lipolysis pathways, or comparing beta-3 AR agonism against full GH axis activation, AOD-9604 and its structural relative HGH Fragment 176-191 represent the primary available research tools. Both are available from Pure Grade Labs as research chemicals for research purposes only. Not for human consumption.
References
- Ng FM, et al. (1990). Metabolic studies with a synthetic fragment of human growth hormone representing residues 177–191. Journal of Molecular Endocrinology. 5(2):139–145.
- Heffernan MA, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 142(12):5182–5189. DOI: 10.1210/endo.142.12.8522
- McMillan M, et al. (2006). AOD-9604: Phase IIb body composition trial outcomes — fat mass reduction in adults. International Journal of Obesity. Data presented at the International Congress on Obesity, Sydney, 2006.
- Stier H, et al. (2013). Safety evaluation of AOD-9604 — supporting the GRAS petition for oral ingredient use. Food and Chemical Toxicology. Review supporting FDA GRAS petition. GRAS notice GRN 000454.
- Ng FM, Bornstein J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. American Journal of Physiology. 234(1):E521–E526.
- Heffernan MA, et al. (2000). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 24(2):131–138.